Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Desarrollada en el mundo por el gigante farma Eli Lilly y comercializada en la regin por Adium (exceptuando Brasil, Mxico y Colombia), es el primer agonista dual de los receptores GIP y GLP-1 aprobado , lo que representa una innovacin teraputica de primera generacin
At least a 50% reduction in eGFR from baseline
The pivotal clinical trials for tirzepatide (SURPASS programme) did not identify diverticulitis as a specific adverse event of concern, as documented in the European Medicines Agency's European Public Assessment Report (EPAR)
Semaglutide, which only acts on the GLP-1 receptor, might be better tolerated in that situation
Lu X, et al
US$ 20.01
US$ 20.43
US$ 29.90
US$ 27.86
US$ 21.03
US$ 29.45
US$ 27.96
US$ 22.39
US$ 22.86
US$ 23.78
